Key result
Prostaglandin E1 undergoes Cochrane protocol evaluation for maintaining ductal patency in neonates with ductus-dependent lesions.
Why the study?
The effectiveness and safety of prostaglandin E1 for maintaining ductus arteriosus patency and reducing mortality in neonates with ductal-dependent cardiac lesions require evaluation.
Does Prostaglandin E1 maintain patency of the ductus arteriosus and decrease mortality in neonates with ductus-dependent cardiac lesions?
Does Prostaglandin E1 maintain patency of the ductus arteriosus and decrease mortality in neonates with ductus-dependent cardiac lesions?
This protocol outlines a planned Cochrane Review to assess the efficacy and safety of Prostaglandin E1 for maintaining ductal patency in neonates with ductus-dependent cardiac lesions.
Answers are grounded in this paper and cite their sources.
No immediate change to PGE1 use in duct-dependent lesions; protocol leaves open definitive efficacy and safety assessment.
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To determine the effectiveness of PGE1 in maintaining patency of the ductus arteriosus and decreasing mortality in ductal‐dependent cardiac lesions and to determine the safety of PGE1 when used in ductal‐dependent cardiac lesions both short term (less than 120 hours) and long term (120 hours or greater).
No takes yet. Share an insight, caveat, or question.
Hundalani et al. (2014) studied this question. Prostaglandin E1 is being evaluated in a Cochrane Review protocol to determine its effectiveness and safety for maintaining ductal patency in neonates with ductus-dependent cardiac lesions.
Synapse has enriched 10 related papers. Consider them for comparative context: